Coverage: LD-2 reports for 2025 onward, posted Jan 1, 2025 through Oct 27, 2026. Only the current version of each report is used.
31,951 report citations, newest first.
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
$1,530,000
Spent on own lobbying
CitesH.R. 7148· this member:Recorded votes on 8 roll calls
…on Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding polic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
$1,530,000
Spent on own lobbying
CitesS. 1071· this member:Recorded votes on 3 roll calls
…lopment; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: Na…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
$1,530,000
Spent on own lobbying
CitesS. 2296· this member:Recorded votes on 12 roll calls
…merce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authoriza…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
$1,530,000
Spent on own lobbying
CitesS. 4784· this member:Recorded vote on 1 roll call
…026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,530,000
Spent on own lobbying
CitesH.R. 1· this member:Recorded votes on 44 roll calls
…S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiat…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,530,000
Spent on own lobbying
CitesS. 1414· this member:Sponsored
…. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act fo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,530,000
Spent on own lobbying
CitesS. 1954· this member:Cosponsored
…Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,530,000
Spent on own lobbying
CitesS. 355· this member:Cosponsored
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$1,530,000
Spent on own lobbying
CitesH.R. 1· this member:Recorded votes on 44 roll calls
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
JPMORGAN CHASE HOLDINGS LLC · lobbying firm or registrant: JPMORGAN CHASE HOLDINGS LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Banking
$1,460,000
Spent on own lobbying
CitesH.R. 6644· this member:Recorded votes on 9 roll calls
S. 401, H.R. 3234, H.R. 6644, S. 4198, H.R. 6955, H.R. 10167 - Discussed bank regulatory policy. Discussed mortgage loan originations, servicing and refinancing, and related issues.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
JPMORGAN CHASE HOLDINGS LLC · lobbying firm or registrant: JPMORGAN CHASE HOLDINGS LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Financial Institutions/Investments/Securities
$1,460,000
Spent on own lobbying
CitesH.R. 3633· this member:Recorded vote on 1 roll call
H.R. 3633, S. 3017, H.R. 1799, H.R. 2152, H.R. 4801, H.R. 8278, H.R. 9925 - Discussed margin issues and CCPs. Discussed issues related to bank structure, capital require…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
JPMORGAN CHASE HOLDINGS LLC · lobbying firm or registrant: JPMORGAN CHASE HOLDINGS LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Homeland Security
$1,460,000
Spent on own lobbying
CitesS. 4784· this member:Recorded vote on 1 roll call
S. 1337, H.R. 5079, H.R. 8800, S. 4784 - Discussed proposals related to cyber security, data protection, notification issues and outbound investment issues. Discussed issues related to establishing…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
APPLIED INTUITION · lobbying firm or registrant: APPLIED INTUITION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$220,000
Spent on own lobbying
CitesS. 4784· this member:Recorded vote on 1 roll call
H.R.9495 - Department of Defense Appropriations Act, 2027; and H.R.8800/S.4784 - National Defense Authorization Act of Fiscal Year 2027: Issues related to the deployment of safe and trusted autonomy.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SOLANA POLICY INSTITUTE · lobbying firm or registrant: FEDERAL HALL POLICY ADVISORS, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Financial Institutions/Investments/Securities
$20,000
Paid to lobbying firm
CitesH.R. 3633· this member:Recorded vote on 1 roll call
…entralized finance, digital rights, regulatory framework for stablecoins, and central bank digital currency regulations and proposals (S. 4428 SAFE Crypto Act; H.R. 3633 CLARITY Act; H.R. 7732 Promoting Innovation in Blockchain Development Act; H.R. 3533/ S. 3611 Blockchain Regulatory Certainty Act; S. 4064 Digital Asset Market…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHATHAM COUNTY · lobbying firm or registrant: CROSS POTOMAC CONSULTING LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$20,000
Paid to lobbying firm
CitesS. 4784· this member:Recorded vote on 1 roll call
…t/economic activities along the coastal Georgia region FY27 Department of Defense Appropriations, H.R. 9495 FY27 National Defense Authorization Act, H.R. 8800, S. 4784
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALLIANCE FOR AUTOMOTIVE INNOVATION · lobbying firm or registrant: ALLIANCE FOR AUTOMOTIVE INNOVATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Automotive Industry
$1,502,541
Spent on own lobbying
CitesH.J.Res. 88· this member:Recorded votes on 2 roll calls
HR 2110: Safe Vehicle Access for Survivors Act HR 9615: Battery Recycling for America's Competitive Economy Act (BRACE) Act H.J.Res.88: California State Motor Vehicle and Engine Pollution Control Standards; Advanced Clean Cars II; Waiver of Preemption S. 315: AM Radio for Every Vehicle Act of…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VISA · lobbying firm or registrant: AVOQ, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Financial Institutions/Investments/Securities
$60,000
Paid to lobbying firm
CitesH.R. 3633· this member:Recorded vote on 1 roll call
…ated to credit card interchange; Issues relating to H.R. 7035/S. 3623, the Credit Card Competition Act; General monitoring of issues related to digital assets; H.R. 3633, Digital Asset Market Clarity Act of 2025; Issues related to artificial intelligence (AI)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MASS VIRTUAL · lobbying firm or registrant: CROSS POTOMAC CONSULTING LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$20,000
Paid to lobbying firm
CitesS. 4784· this member:Recorded vote on 1 roll call
…ughout the Department of Defense and Military Services FY27 Department of Defense Appropriations, H.R. 9495 FY27 National Defense Authorization Act, H.R. 8800, S. 4784
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MENET AERO · lobbying firm or registrant: CROSS POTOMAC CONSULTING LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
CitesS. 4784· this member:Recorded vote on 1 roll call
…capabilities throughout DOD and the Military Services FY27 Department of Defense Appropriations, H.R. 9495 FY27 National Defense Authorization Act, H.R. 8800, S. 4784
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. View filing
QUANTUM KNIGHT · lobbying firm or registrant: OCULUS STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
CitesS. 4784· this member:Recorded vote on 1 roll call
H.R. 9495, S. ____ FY27 Defense Appropriations Act (RDT&E Sections) H.R. 8800, S. 4784 FY27 National Defense Authorization Act Issues related to post-quantum cryptography
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
JCB, INC. · lobbying firm or registrant: CROSS POTOMAC CONSULTING LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$50,000
Paid to lobbying firm
CitesS. 4784· this member:Recorded vote on 1 roll call
…ovided to US military services and government agencies FY27 Department of Defense Appropriations, H.R. 9495 FY27 National Defense Authorization Act, H.R. 8800, S. 4784
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · lobbying firm or registrant: COVINGTON & BURLING LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$340,000
Paid to lobbying firm
CitesS. 1414· this member:Sponsored
…36; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · lobbying firm or registrant: COVINGTON & BURLING LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$340,000
Paid to lobbying firm
CitesS. 1954· this member:Cosponsored
…Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled dis…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · lobbying firm or registrant: COVINGTON & BURLING LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$340,000
Paid to lobbying firm
CitesS. 4784· this member:Recorded vote on 1 roll call
…ential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SAVANNAH AREA CHAMBER OF COMMERCE · lobbying firm or registrant: CROSS POTOMAC CONSULTING LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$12,000
Paid to lobbying firm
CitesS. 4784· this member:Recorded vote on 1 roll call
…t/economic activities along the coastal Georgia region FY27 Department of Defense Appropriations, H.R. 9495 FY27 National Defense Authorization Act, H.R. 8800, S. 4784
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
